Parathyroid hormone

Generic Name: Parathyroid hormone

Brand Names: Natpara, Natpar

Drug Type: Biotech

CAS Number: 9002-64-6

Unique Ingredient Identifier: N19A0T0E5J

Background: Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa).

Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).

Indication: For use/treatment in osteoporosis.

Associated Conditions: Hypocalcemia, Hypoparathyroidism

Clinical Trials

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: placebo
Drug: ALX1-11 50 mcg
Drug: ALX1-11 75mcg
Drug: ALX1-11

First Posted Date: 2005-09-15

Last Posted Date: 2021-05-17

Lead Sponsor: Shire

Target Recruit Count: 217

Registration Number: NCT00172107

Locations: 🇺🇸
Paul Miller, Lakewood, Colorado, United States
🇺🇸
Steven Harris, Mill Valley, California, United States
🇺🇸
Radiant Research, Stuart, Stuart, Florida, United States

and more 16 locations

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: placebo
Drug: ALX1-11

First Posted Date: 2005-09-15

Last Posted Date: 2021-05-14

Lead Sponsor: Shire

Target Recruit Count: 2532

Registration Number: NCT00172081

Locations: 🇺🇸
'East Bay Clinical Trial Center, Concord, California, United States
🇺🇸
'Community Research Centers, Santa Ana, California, United States
🇺🇸
Rush-Prebyterian-St.Luke's Medical Center, Chicago, Illinois, United States

and more 165 locations

rhPTH Therapy for Low Turnover Bone Fragility

Phase 1

Terminated

Conditions: Osteopetrosis

Interventions: Drug: rhPTH

First Posted Date: 2005-09-05

Last Posted Date: 2016-01-12

Lead Sponsor: University of Chicago

Target Recruit Count: 2

Registration Number: NCT00145886

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Treatment of Psoriasis With Parathyroid Hormone

Phase 1

Completed

Conditions: Plaque Psoriasis

First Posted Date: 2000-12-18

Last Posted Date: 2007-01-04

Lead Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Target Recruit Count: 40

Registration Number: NCT00007306

Locations: 🇺🇸
Boston University School of Medicine, Boston, Massachusetts, United States

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: Alendronate
Drug: Parathyroid Hormone
Drug: Teriparatide

First Posted Date: 2000-03-27

Last Posted Date: 2015-08-19

Lead Sponsor: Helen Hayes Hospital

Target Recruit Count: 140

Registration Number: NCT00005006

Locations: 🇺🇸
Helen Hayes Hospital, Clinical Research Center, West Haverstraw, New York, United States

PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: PTH
Drug: Alendronate

First Posted Date: 2000-03-27

Last Posted Date: 2013-02-05

Lead Sponsor: Dennis Black

Target Recruit Count: 238

Registration Number: NCT00005005

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Maine Center for Osteoporosis, Bangor, Maine, United States

and more 1 locations